(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Most Moving TED Talks You Want to Watch - 2The Way to Business: Startup Illustrations Learned
- 3Single women risk rape and exploitation in search for better life in Europe
- 4Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- 5Health insurance premiums rose nearly 3x the rate of worker earnings over the past 25 years
- Iran warns its ready to open new front in Yemen, close Bab al-Mandab Strait with Houthis
- Israel’s mixed messaging on Christmas draws controversy
- 'Not the moon that I'm used to seeing': Artemis II astronauts describe seeing the far side
- Day to day Temporary Positions That Compensate Fairly in the US
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- Vote In favor of Your Favored Cereal
- Liste des pr\u00eats qui ne n\u00e9cessitent pas de remboursement
- 5 Chiefs That Changed Our Opinion on Film
- The most effective method to Promoter for Cellular breakdown in the lungs Mindfulness in Your People group
